SCHEMBL40256

SCHEMBL40256

OB(O)c1ccc(CBr)cc1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LPL P06858 7/20 0.58
LIPG Q9Y5X9 7/20 0.58
F11 P03951 1/20 0.56
CA2 P00918 4/20 0.52
CA1 P00915 3/20 0.52
TSHR P16473 2/20 0.52
ENPP2 Q13822 3/20 0.48
MGLL Q99685 2/20 0.47
TRPV1 Q8NER1 1/20 0.47
CA4 P22748 1/20 0.43
CA6 P23280 1/20 0.43
CA5A P35218 1/20 0.43
CA7 P43166 1/20 0.43
CA14 Q9ULX7 1/20 0.43
CA5B Q9Y2D0 1/20 0.43
TRPA1 O75762 1/20 0.43
ALDH1A1 P00352 1/20 0.43
KDM4E B2RXH2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28429722 0.87 LPL (0.52) LPLLIPGF11CA2CA1
Ether SCHEMBL28233827 0.85 LPL (0.55) LPLLIPGF11CA2CA1
SCHEMBL9145073 0.80 LPL (0.61) LPLLIPGF11CA2CA1
SCHEMBL7283359 0.78 TSHR (0.39) LPLLIPGF11CA2CA1
SCHEMBL13667094 0.78 LPL (0.64) LPLLIPGF11CA2CA1
SCHEMBL890400 0.78 LPL (0.73) LPLLIPGF11CA2CA1
SCHEMBL204921 0.76 ENPP2 (0.73) LPLLIPGF11CA2CA1
SCHEMBL131361 0.76 ALDH1A1 (0.67) TSHRTRPA1ALDH1A1
SCHEMBL112402 0.76 LPL (0.61) LPLLIPGF11CA2CA1
SCHEMBL23406327 0.74 LPL (0.58) LPLLIPGF11CA2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 761 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122057086-A Implanted microneedle anastomosis stent, and preparation method and application thereof 浙江大学 2026-05-19 CN claimed
CN-122005434-A ROS responsive hydrogel eye drop preparation, preparation method thereof and application thereof in cornea disease treatment 山西医科大学 2026-05-12 CN claimed
US-20250320313-A1 METHOD FOR PREPARING POLY(IONIC LIQUID) (PIL)-FUNCTIONALIZED CELLULOSE CONDUCTIVE HYDROGEL SHAANXI UNIV OF SCIENCE & TECHNOLOGY (CN) 2025-10-16 US claimed
CN-120132050-A ROS sensitive hydrogel composite polycaprolactone scaffold and preparation method and application thereof 广西医科大学 2025-06-13 CN claimed
CN-120131953-A Targeted nano-drug with sonodynamic activity, and preparation method and application thereof 中山大学·深圳 2025-06-13 CN claimed
CN-120078705-A Exosome-coated response type drug-loaded dendrimer nanogel system and preparation method and application thereof 东华大学 2025-06-03 CN claimed
CN-116203006-B Multichannel fluorescent array sensor and construction and use method thereof 中国药科大学 2025-04-25 CN claimed
CN-119684674-A Glycoprotein imprinted polymer based on boric acid functional group-containing imidazole ionic liquid monomer, and preparation method and application thereof 西京学院 2025-03-25 CN claimed
CN-119564885-A Double-lock type viroid fluorescent nano probe for monitoring virus infection process, preparation method and application 南开大学 2025-03-07 CN claimed
CN-119455020-A Multilayer composite drug-loaded nano motor and preparation method and application thereof 南京鼓楼医院 2025-02-18 CN claimed
CN-108299485-B Fluorescent probe for detecting hydrogen peroxide in living cells and preparation method and application thereof 湖北大学 2020-05-12 CN claimed
CN-111097520-A Covalent organic framework material loaded Pd catalyst and preparation method and application thereof 中国科学院广州能源研究所 2020-05-05 CN claimed
CN-110882397-A ATP (adenosine triphosphate) response type nano micelle, preparation method and application 上海市肿瘤研究所 2020-03-17 CN claimed
CN-110642882-A Fluorescent probe with hydrogen peroxide detection and photodynamic cancer cell killing activity as well as preparation method and application thereof 内蒙古大学 2020-01-03 CN claimed
US-20180312617-A1 A CATION POLYMER CAPABLE OF REMOVING POSITIVE CHARGES THROUGH OXIDATIVE RESPONSE, A PREPARATION METHOD AND APPLICATION ZHEJIANG UNIVERSITY (CN) 2018-11-01 US claimed
EP-1885714-B1 PROCESS FOR THE PREPARATION OF 2-ALKYL-1-((2'-SUBSTITUTED-BIPHENYL-4-YL)METHYL)-IMIDAZOLE, DIHYDROIMIDAZOLE OR BENZIMIDAZOLE DERIVATIVES LEK PHARMACEUTICALS (SI) 2014-01-15 EP claimed
US-20090176849-A1 Process for the preparation of 2-alkyl-1-((2'-substituted-biphenyl-4-yl) Methyl)-imidazole, dihydroimidazole or benzimidazloe derivatives LEK PHARMACEUTICALS, D.D. (SI) 2009-07-09 US claimed
EP-1885714-A2 PROCESS FOR THE PREPARATION OF 2-ALKYL-1-((2'-SUBSTITUTED-BIPHENYL-4-YL)METHYL)-IMIDAZOLE, DIHYDROIMIDAZOLE OR BENZIMIDAZOLE DERIVATIVES LEK Pharmaceuticals D.D. (SI) 2008-02-13 EP claimed
WO-2006125592-A2 PROCESS FOR THE PREPARATION OF 2-ALKYL-1-((2'-SUBSTITUTED-BIPHENYL-4-YL)METHYL)-IMIDAZOLE, DIHYDROIMIDAZOLE OR BENZIMIDAZOLE DERIVATIVES LEK PHARMACEUTICALS D.D. (SI) 2006-11-30 WO claimed
EP-1009451-B1 COMPOSITIONS AND THEIR USE TO PREVENT FORMATION OF ADHESIONS IN BIOLOGICAL TISSUES CALIFORNIA INST OF TECHN (US) 2003-10-29 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180312617-A1 A CATION POLYMER CAPABLE OF REMOVING POSITIVE CHARGES THROUGH OXIDATIVE RESPONSE, A PREPARATION METHOD AND APPLICATION PBRM1, SLC7A1, PHAX LPL 4318/4885LIPG 4118/4885F11 3355/4885
US-20090176849-A1 Process for the preparation of 2-alkyl-1-((2'-substituted-biphenyl-4-yl) Methyl)-imidazole, dihydroimidazole or benzimidazloe derivatives AGTR1, AGTR2, REN LPL 4261/4885LIPG 3937/4885F11 3367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.